Results 21 to 30 of about 1,668 (203)

Asymmetrical putaminal atrophy in parkinsonism-predominant multiple system atrophy (MSA-P): A case report

open access: yesRadiology Case Reports, 2023
We encountered a case of multiple system atrophy parkinsonian subtype (MSA-P) with right-dominant parkinsonism in the early stage of the disease. Atrophy of the posterolateral putamen and iron deposition are the neuropathological hallmark of MSA-P ...
Koichiro Mori, MD   +2 more
doaj   +1 more source

A lipid nanoparticle-based oligodendrocyte-specific mRNA therapy

open access: yesMolecular Therapy: Nucleic Acids
Despite the wide range of applications of mRNA therapies, major difficulties exist in the efficient delivery of mRNA into oligodendrocytes, a type of glial cell in the brain. Commonly used viral vectors are not efficient in transforming oligodendrocytes.
Masanori Sawamura   +13 more
doaj   +1 more source

Dystonia in multiple system atrophy [PDF]

open access: yesJournal of Neurology, Neurosurgery & Psychiatry, 2002
To delineate the frequency and nature of dystonia in multiple system atrophy (MSA).A cohort of 24 patients with clinically probable MSA over the past 10 years were prospectively followed up. Motor features were either dominated by parkinsonism (MSA-P subtype, n=18) or cerebellar ataxia (MSA-C, n=6). Classification of dystonic features and their changes
S M, Boesch   +3 more
openaire   +2 more sources

External anal sphincter electromyography in multiple system atrophy: implications for diagnosis, clinical correlations, and novel insights into prognosis

open access: yesNeural Regeneration Research, 2023
Multiple system atrophy is a sporadic, progressive, adult-onset, neurodegenerative disorder characterized by autonomic dysfunction symptoms, parkinsonian features, and cerebellar signs in various combinations.
Massimiliano Todisco   +2 more
doaj   +1 more source

Fibril-seeded animal models of synucleinopathies: Pathological mechanisms, disease modeling, and therapeutic implications

open access: yesNeuroscience Research
Accumulating evidence suggests that prion-like spread of misfolded α-Synuclein (αSyn) underlies the pathological progression of Lewy body diseases (LBD).
Norihito Uemura
doaj   +1 more source

Diagnosis of multiple system atrophy [PDF]

open access: yesAutonomic Neuroscience, 2018
Multiple system atrophy (MSA) may be difficult to distinguish clinically from other disorders, particularly in the early stages of the disease. An autonomic-only presentation can be indistinguishable from pure autonomic failure. Patients presenting with parkinsonism may be misdiagnosed as having Parkinson disease.
Jose-Alberto Palma   +2 more
openaire   +2 more sources

Impact of α-synuclein fibril structure on seeding activity in experimental models of Parkinson’s disease

open access: yesnpj Parkinson's Disease
The central pathogenesis of Parkinson’s disease involves the misfolding and aggregation of α-synuclein (α-syn). There is a widespread belief that α-syn can propagate in a prion-like manner, and α-syn preformed fibrils (PFFs) have been widely used to ...
Junichiro Ohira   +11 more
doaj   +1 more source

Luminescent conjugated oligothiophenes distinguish between α-synuclein assemblies of Parkinson’s disease and multiple system atrophy

open access: yesActa Neuropathologica Communications, 2019
Synucleinopathies [Parkinson’s disease with or without dementia, dementia with Lewy bodies and multiple system atrophy] are neurodegenerative diseases that are defined by the presence of filamentous α-synuclein inclusions.
Therése Klingstedt   +5 more
doaj   +1 more source

Cutaneous silent periods in multiple system atrophy

open access: yesBiomedical Papers, 2015
Aim: The cutaneous silent period (CSP) is a spinal inhibitory reflex primarily mediated by A-delta fibers. Prolonged CSPs have been reported in patients with restless legs syndrome (RLS) and idiopathic Parkinson's disease (IPD).
Ivana Stetkarova   +2 more
doaj   +1 more source

Comparative Evaluation of Hemodiafiltration, Hemoperfusion, and Standard Hemodialysis on Efficacy, Inflammatory Control, Dialysis Adequacy, and Safety in End‐Stage Renal Disease: A Prospective Observational Study

open access: yesTherapeutic Apheresis and Dialysis, EarlyView.
ABSTRACT Background Chronic micro‐inflammation in patients with end‐stage renal disease (ESRD) is a significant driver of cardiovascular complications and diminished quality of life. While standard hemodialysis (SHD) effectively manages small‐molecule clearance, its ability to remove medium‐to‐large uremic toxins—the primary catalysts of systemic ...
Hongwei Zuo   +5 more
wiley   +1 more source

Home - About - Disclaimer - Privacy